What's The BUZZ?

Market News, Products, Services, and Trends

Advertisement

Ep 22 – 340B Growth in Context: What the Data Really Shows

Ep 22 – 340B Growth in Context: What the Data Really Shows

340B growth is real. But dollar-term growth doesn’t tell the full story.

In the latest episode of Katy’s 340B Compass, Katy Lees examines why rising 340B spending should be evaluated in the context of drug acquisition costs, patient complexity, and broader healthcare pressures.

The key distinction is simple but important: price, total spending, utilization, and patient acuity are not the same measure. Treating them as interchangeable can distort the conversation and weaken policy and governance decisions.

For health system executives, compliance leaders, CFOs, pharmacy leaders, and governance teams, this episode offers a clearer framework for understanding 340B growth with greater operational awareness and leadership clarity.

Visit Virtue 340B’s website to watch the episode on YouTube or listen on Spotify and other podcast platforms. Watch now >

Virtue 340B

Virtue 340B News & Announcements

Virtue 340B® provides independent 340B risk oversight for hospitals and health systems operating in an increasingly complex and scrutinized program environment. Rather than managing programs or selling technology, Virtue delivers objective, independent analysis that helps leadership understand where hidden exposure may exist, what that exposure could mean operationally or financially, and whether current oversight would stand up under external scrutiny. Our work translates complex 340B operational realities into clear, defensible insights that executives can act on with confidence.
Through independent audits, mock HRSA audit simulations, and continuous compliance monitoring, Virtue 340B® helps organizations detect operational drift early, strengthen oversight structures, and maintain durable, audit-ready programs. By focusing on prevention, visibility, and governance, not just technical compliance, Virtue 340B equips leadership teams with the clarity they need to protect their organizations and confidently defend how their 340B programs are being managed.

RXinsider Staff

Posted by: RXinsider Staff

RXinsider is a multimedia publishing and technology company offering print publications, digital platforms, events, and content creation services to the B2B pharmacy market.

SUBSCRIBE

Name
Subscription Choices
Checkboxes
Subscribe
Receive the latest news, product launches, and insights from RXinsider.

Request information from Ep 22 – 340B Growth in Context: What the Data Really Shows

Name
Address
Subscribe